Type

Blood

Infection & Inflammation

Part of

Infection & Inflammation

Blood biomarker

Part of

Infection & Inflammation

Anti-Cyclic Citrullinated Peptide Antibodies (Anti-CCP)

EBV antibodies are immune proteins that indicate past or current Epstein-Barr virus infection, which causes mono.

Anti-Cyclic Citrullinated Peptide Antibodies (Anti-CCP)

Normal range

Negative (<7U/mL)

Normal range

Negative (<7U/mL)

Normal range

Anti-Cyclic Citrullinated Peptide Antibodies (Anti-CCP)

EBV antibodies are immune proteins that indicate past or current Epstein-Barr virus infection, which causes mono.

Anti-Cyclic Citrullinated Peptide Antibodies (Anti-CCP)

Normal range

Negative (<7U/mL)

Normal range

Negative (<7U/mL)

Normal range

Anti-Cyclic Citrullinated Peptide Antibodies (Anti-CCP)

EBV antibodies are immune proteins that indicate past or current Epstein-Barr virus infection, which causes mono.

Anti-Cyclic Citrullinated Peptide Antibodies (Anti-CCP)

Normal range

Negative (<7U/mL)

Normal range

Negative (<7U/mL)

Normal range

Anti-Cyclic Citrullinated Peptide Antibodies (Anti-CCP)

Dr. Jack Devin

MBBS

Your Rheumatoid Arthritis Early Warning System

Your immune system normally protects you from harmful invaders, but sometimes it can mistakenly target your own body's tissues. Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibodies represent one such case—these are autoantibodies that specifically attack proteins in your joint tissues that have undergone a particular chemical change called citrullination. When your body produces these antibodies, they can signal the development of rheumatoid arthritis, often years before joint pain and swelling become obvious.

More than 90% of rheumatoid arthritis patients produce these types of antibodies. This process may well be the cause of the inflammatory process since citrullinated proteins and the enzymes responsible for producing them are found in inflamed synovium. Anti-CCP testing has revolutionised early rheumatoid arthritis diagnosis because these antibodies are remarkably specific—they rarely appear in healthy people or those with other joint conditions, making them excellent markers for distinguishing rheumatoid arthritis from other causes of joint problems.

Get tested

When Anti-CCP Levels Signal Joint Inflammation

Discover how these specific antibodies indicate rheumatoid arthritis development and what their presence means for your joint health.

What Triggers Anti-CCP Antibody Production

From genetic factors to environmental triggers, learn what can cause your immune system to produce these joint-targeting antibodies.

The Anti-CCP-Rheumatoid Arthritis Connection

Understanding how this test helps diagnose rheumatoid arthritis early and predict disease progression and joint damage.

Understanding Your Results

Decode your antibody levels and know exactly what your results mean for rheumatoid arthritis diagnosis and treatment planning.

When Anti-CCP Levels Signal Joint Inflammation

Normal Anti-CCP levels indicate that your immune system isn't producing significant amounts of these joint-targeting antibodies. The normal level of anti-CCP is less than 20 U/mL. People with values significantly higher than this reference range may have or be at risk for rheumatoid arthritis.

The presence of Anti-CCP antibodies often appears months or even years before joint symptoms develop. These antibodies tend to persist once they appear, providing consistent evidence of the autoimmune process underlying rheumatoid arthritis.

With a specificity of about 96% and a positive likelihood ratio of about 14, anti-CCP assists with the diagnosis of RA. It is present in only a quarter to half of patients before or at diagnosis, so a negative result does not rule out RA. This high specificity means that if you test positive for Anti-CCP, there's a high chance you have or will develop rheumatoid arthritis.

When Anti-CCP Levels Signal Joint Inflammation

What Triggers Anti-CCP Antibody Production

Genetic predisposition plays a significant role in Anti-CCP antibody development, with certain genetic variants making some people more susceptible to developing these autoantibodies when exposed to environmental triggers. Having these genetic factors doesn't guarantee you'll develop rheumatoid arthritis, but it does increase your risk if other conditions align.

Environmental factors including smoking, infections, and exposure to certain chemicals can trigger the process that leads to Anti-CCP antibody production. Smoking is particularly important because it can increase both the likelihood of developing these antibodies and the severity of rheumatoid arthritis if it develops.

The citrullination process occurs when specific enzymes modify proteins in joint tissues, changing their structure in ways that make your immune system view them as foreign invaders. This process can be triggered by inflammation, tissue stress, or immune system activation, creating the modified proteins that Anti-CCP antibodies target.

Hormonal factors may influence Anti-CCP antibody production, with some studies suggesting that hormonal changes during pregnancy, menopause, or other life stages might affect autoantibody development. These influences help explain why rheumatoid arthritis affects women more frequently than men.

Periodontal disease has emerged as a potential trigger for Anti-CCP antibody production, as the bacteria involved in gum disease can promote citrullination processes. Maintaining good oral health may therefore play a role in preventing or reducing autoantibody development in susceptible individuals.

What Triggers Anti-CCP Antibody Production

The Anti-CCP-Rheumatoid Arthritis Connection

Anti-CCP is currently seen as a more specific marker for the diagnosis of rheumatoid arthritis than rheumatoid factor, providing more reliable diagnostic information with fewer false positives. This specificity makes Anti-CCP testing particularly valuable when rheumatoid arthritis is suspected but other tests are inconclusive.

The 2009 NICE guidelines recommend considering anti-cyclic citrullinated peptide (CCP) antibodies in people with suspected RA if they are negative for rheumatoid factor, highlighting how this test complements traditional rheumatoid arthritis screening. Anti-CCP antibodies are markers for diagnosis and prognosis in rheumatoid arthritis (RA). The presence of these antibodies not only helps confirm diagnosis but also provides information about likely disease course and treatment response.

The prognostic value of Anti-CCP extends beyond simple diagnosis to include prediction of joint damage progression, treatment response, and long-term outcomes. People with higher Anti-CCP levels often experience more aggressive disease requiring more intensive treatment, whilst those with lower levels may have milder disease.

The Anti-CCP-Rheumatoid Arthritis Connection

Get started

Understanding Your Results

Normal (negative): <20 U/mL
Positive: ≥20 U/mL

Once positive, Anti-CCP antibodies typically remain elevated, so repeat testing isn't usually necessary. However, people with positive results need regular monitoring for rheumatoid arthritis development and joint pain or swelling.

Understanding Your Results

Normal (negative): <20 U/mL
Positive: ≥20 U/mL

The Takeaway

Anti-CCP testing provides powerful early detection capabilities for rheumatoid arthritis, often identifying the autoimmune process years before joint issues become apparent. If your Anti-CCP levels are elevated, there is a higher risk for rheumatoid arthritis and should be interpreted alongside any symptoms such as joint pain.

A simple blood test can reveal whether your immune system is producing antibodies that target your joint tissues, providing vital diagnostic information.

The Takeaway

A simple blood test can reveal whether your immune system is producing antibodies that target your joint tissues, providing vital diagnostic information.

References

South Tees Hospitals NHS Foundation Trust. (2025). Cyclic Citrullinated Peptide (CCP) Antibody. NHS Foundation Trust Guidelines.
Newcastle Hospitals NHS Foundation Trust. (2024). CCP Antibodies Laboratory Test Information. NHS Laboratories Clinical Standards.
Leeds Teaching Hospitals NHS Trust. (2024). Anti-Cyclic Citrullinate Peptide (CCP) Antibodies Testing Guidelines. NHS Trust Clinical Protocols.
Royal United Hospital Bath NHS Trust. (2024). Anti-CCP Antibodies Clinical Application Guidelines. NHS Foundation Trust Laboratory Medicine.

References

South Tees Hospitals NHS Foundation Trust. (2025). Cyclic Citrullinated Peptide (CCP) Antibody. NHS Foundation Trust Guidelines.
Newcastle Hospitals NHS Foundation Trust. (2024). CCP Antibodies Laboratory Test Information. NHS Laboratories Clinical Standards.
Leeds Teaching Hospitals NHS Trust. (2024). Anti-Cyclic Citrullinate Peptide (CCP) Antibodies Testing Guidelines. NHS Trust Clinical Protocols.
Royal United Hospital Bath NHS Trust. (2024). Anti-CCP Antibodies Clinical Application Guidelines. NHS Foundation Trust Laboratory Medicine.